Journal of gastroenterology · 2026
HOXC9 enhances cholesterol metabolism and malignancy in pancreatic ductal adenocarcinoma through ITGA10/FAK/PI3K/CREB-dependent HMGCR activation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Futang, Yang Ming, Sun Xinghao, Chen Liwen, Zheng Dijie, Wei Zikai, Gong Yanyu, He Zhiwei, Yu Chao
Аннотация
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. Dysregulated cholesterol metabolism contributes to tumor progression, but its regulatory mechanisms in PDAC are unclear. This study explored the role and mechanism of homeobox C9 (HOXC9) in cholesterol regulation and PDAC development.
METHODS: HOXC9 was identified by bioinformatics as a key cholesterol metabolism gene in PDAC. Its expression was validated via qRT-PCR, Western blot, and immunohistochemistry, while cholesterol were measured using microassay and Filipin III staining. In vitro assays and subcutaneous tumor models in nude mice were used to assess its functional roles. RNA-seq, ChIP-qPCR, and dual-luciferase reporter assays explored molecular mechanisms.
RESULTS: HOXC9 was identified as a key cholesterol metabolism-related transcription factor in PDAC. High-throughput data analysis based on TCGA databases further revealed that HOXC9 was highly expressed in PDAC tissues and associated with dismal prognosis. Clinically, HOXC9 upregulation correlates positively with tumor cholesterol, advanced stage, and reduced survival. Functionally, HOXC9 promotes PDAC cell proliferation, migration, and invasion in a cholesterol-dependent manner. In vivo, HOXC9 knockdown suppressed tumor growth and intratumoral cholesterol in nude mice, an effect reversible by high-cholesterol diet. Mechanistically, transcriptome sequencing highlighted the PI3K-Akt pathway as a key downstream target. HOXC9 transcriptionally activates ITGA10, which upregulates HMGCR via the FAK/PI3K/CREB, thereby driving cholesterol metabolism and tumor progression.
CONCLUSIONS: HOXC9 may be a key transcriptional regulator of cholesterol metabolism in PDAC, promoting malignant progression by activating the ITGA10/FAK/PI3K/CREB to regulate HMGCR-mediated cholesterol synthesis. The essential role of the HOXC9-ITGA10-cholesterol axis in PDAC progression offers a novel potential target for therapy.
METHODS: HOXC9 was identified by bioinformatics as a key cholesterol metabolism gene in PDAC. Its expression was validated via qRT-PCR, Western blot, and immunohistochemistry, while cholesterol were measured using microassay and Filipin III staining. In vitro assays and subcutaneous tumor models in nude mice were used to assess its functional roles. RNA-seq, ChIP-qPCR, and dual-luciferase reporter assays explored molecular mechanisms.
RESULTS: HOXC9 was identified as a key cholesterol metabolism-related transcription factor in PDAC. High-throughput data analysis based on TCGA databases further revealed that HOXC9 was highly expressed in PDAC tissues and associated with dismal prognosis. Clinically, HOXC9 upregulation correlates positively with tumor cholesterol, advanced stage, and reduced survival. Functionally, HOXC9 promotes PDAC cell proliferation, migration, and invasion in a cholesterol-dependent manner. In vivo, HOXC9 knockdown suppressed tumor growth and intratumoral cholesterol in nude mice, an effect reversible by high-cholesterol diet. Mechanistically, transcriptome sequencing highlighted the PI3K-Akt pathway as a key downstream target. HOXC9 transcriptionally activates ITGA10, which upregulates HMGCR via the FAK/PI3K/CREB, thereby driving cholesterol metabolism and tumor progression.
CONCLUSIONS: HOXC9 may be a key transcriptional regulator of cholesterol metabolism in PDAC, promoting malignant progression by activating the ITGA10/FAK/PI3K/CREB to regulate HMGCR-mediated cholesterol synthesis. The essential role of the HOXC9-ITGA10-cholesterol axis in PDAC progression offers a novel potential target for therapy.